Next-Generation Antibody Therapies
Our approach consists of two technology platforms: our DiversImmune® platform, which we use to generate therapeutic “building blocks,” which are high affinity and high specificity antibodies with functional activity against therapeutic targets; and our MultiMabTM platform, which we use to construct therapeutic product candidates by assembling the building blocks into different combinations of bi- and multi-specific antibodies. Together, these platforms support our strategy of building a broad pipeline of next generation antibody therapeutics that are designed to address a wide range of human diseases.
DiversImmune® Antibody Discovery Platform
Create antibody therapies against traditionally difficult targets
MultiMab™ Antibody Engineering Platform
Enhance efficacy and safety: fine-tuning antibody product formats for optimal results
TetraBi Antibody Format for T-cell Engagement
We are building a pipeline of T-cell engagers based on a tetravalent bispecific (TetraBi) format.
We believe the TetraBi antibody format offers several significant competitive advantages:
- Bivalent binding to tumor associated antigen (“TAA”) for potentially increased efficacy
- Fc modification for reducing toxicity and increasing antibody half life
- Flexible configuration for increased safety and/or maximized efficacy
- Symmetrical structure for streamlined manufacturing